Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sunesis Pharmaceuticals, Inc.    SNSS

SUNESIS PHARMACEUTICALS, INC. (SNSS)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 04:00:00 pm
0.472 USD   -19.82%
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

SUNESIS PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 05:30pm EST

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or

Standard; Transfer of Listing.

On January 11, 2019, Sunesis Pharmaceuticals, Inc., or the Company, received a letter from the Listing Qualifications Department, or the Staff, notifying the Company that in accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has been granted an additional 180 calendar days, or until July 10, 2019, to regain compliance with the minimum $1.00 per share requirement for continued inclusion on The NASDAQ Capital Market pursuant to NASDAQ Listing Rule 5550(a)(2), or the Rule. If, at any time before July 10, 2019, the bid price of the Company's common stock closes at $1.00 or more for a minimum of ten consecutive business days as required under NASDAQ Listing Rule 5810(c)(3)(A), unless the Staff exercises its discretion to extend this ten-day period pursuant to NASDAQ Listing Rule 5810(c)(3)(F), the Staff will provide written notification to the Company that it complies with the Rule.

If the Company does not regain compliance with the Rule by July 10, 2019, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a NASDAQ Hearings Panel, or the Panel. The Company would remain listed pending the Panel's decision. There can be no assurance that, if the Company does appeal the delisting determination by the Staff to the Panel, that such appeal would be successful.

The Company is considering actions that it may take in response to this notification in order to regain compliance with the continued listing requirements.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SUNESIS PHARMACEUTICALS, I
01/17SUNESIS PHARMACEUTICALS : Announces Pricing of $20 Million Offering of Securitie..
AQ
01/17Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stoc..
GL
01/11SUNESIS PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Contin..
AQ
01/07SUNESIS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (f..
AQ
01/03SUNESIS PHARMACEUTICALS : Announces Advancement into 100mg Cohort of Phase 1b/2 ..
AQ
01/02Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2..
GL
2018SUNESIS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (f..
AQ
2018SUNESIS PHARMACEUTICALS : Announces Presentation of Preliminary Data from Phase ..
AQ
2018Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase..
GL
2018SUNESIS PHARMACEUTICALS : to Provide Program Update for Non-Covalent BTK-Inhibit..
AQ
More news
Financials ($)
Sales 2018 0,43 M
EBIT 2018 -27,3 M
Net income 2018 -28,2 M
Debt 2018 5,29 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 52,8x
EV / Sales 2019 60,6x
Capitalization 17,7 M
Chart SUNESIS PHARMACEUTICALS, INC.
Duration : Period :
Sunesis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUNESIS PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 0,50 $
Spread / Average Target 5,9%
EPS Revisions
Managers
NameTitle
Dayton Misfeldt Chief Executive Officer & Director
James W. Young Non-Executive Chairman
Deepali Suri Vice President-Clinical Operations
Willie P. Quinn CFO, Senior VP-Finance & Corporate Development
Judith A. Fox Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
SUNESIS PHARMACEUTICALS, INC.13.54%18
IQVIA HOLDINGS INC6.82%25 444
CELLTRION, INC.--.--%22 863
LONZA GROUP8.95%20 746
INCYTE CORPORATION23.32%16 688
SEATTLE GENETICS, INC.29.92%11 878